Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02876978
Recruitment Status : Unknown
Verified August 2016 by CARsgen Therapeutics Co., Ltd..
Recruitment status was:  Recruiting
First Posted : August 24, 2016
Last Update Posted : August 24, 2016
Information provided by (Responsible Party):
CARsgen Therapeutics Co., Ltd.

Brief Summary:
The purpose of this study is to observe and confirm the safety, tolerance and cell pharmacokinetics of lentivirus-transduced CAR-GPC3 T cells (CAR-GPC3 T cells targeting GPC3)

Condition or disease Intervention/treatment Phase
Lung Squamous Cell Carcinoma Genetic: CAR-GPC3 T Cells Drug: Fludarabine Drug: Cyclophosphamide Phase 1

Detailed Description:

A single-center, open-label pilot study to determine the safety, tolerance and engraftment potential of CAR-GPC3 T cells in subjects with GPC3+ positive lung squamous cell carcinoma.

Primary objectives:

Observe and determine the safety and tolerance in escalating dose infusion of CAR-GPC3 T cells (CAR T cells targeting GPC3) transduced with the lentiviral vector, and the survival of the CAT-GPC3 T cells in vivo, referred to as engraftment potential.

Secondary objectives:

The following indexes are monitored for curative effect of CAR-GPC3 T cells on lung squamous cell carcinoma:

  1. Objective response rate (ORR), is defined as the ratio of patients diagnosed as partial remission (PR) to complete remission (CR) according to RECIST 1.1 criteria.
  2. Progression free survival (PFS), is defined as the duration from baseline to PD (audited and confirmed by independent imaging), or to the day of any death event. The earlier one shall prevail.
  3. Time to tumor progression (TTP), is defined as the duration from baseline to disease starts to get worse or spreads to other parts of the body.
  4. Overall survival (OS), is defined as the time period from the 1st day of treatment to the day of death for any reason. For patients who are still alive at the data analysis day, OS data is subject to the last confirmed time of survival patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting GPC3 for the Treatment of Recurrent or Refractory Lung Squamous Cell Carcinoma
Study Start Date : March 2016
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : April 2019

Arm Intervention/treatment
Experimental: CAR-GPC3 T cells

Intravenous infusion with escalating dose is adopted in this study.

Total dosage: 1 x 10^5 - 2 x 10^9 CAR-GPC3 T cells/kg

The next dose and interval depends on the response of the subject to previous dose.


Fludarabine: 30 mg/m^2/day x 4 days; Cyclophosphamide: 500 mg/m^2/day x 2 days. Adjustment is in discretion of the investigator based on individual response.

Genetic: CAR-GPC3 T Cells
Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
Other Names:
  • Anti-GPC3 CAR T
  • CAR T cells redirected to Glypican-3

Drug: Fludarabine
30 mg/m^2/day x 4 days

Drug: Cyclophosphamide
500 mg/m^2/day x 2 days

Primary Outcome Measures :
  1. Safety and tolerance: Occurrence of study related adverse events [ Time Frame: 24 weeks ]
    Occurrence of study related adverse events, defined as laboratory toxicities and clinical events that are possibly, likely or definitely related to study treatment at any time from the infusion until week 24. This will include infusive toxicity, and any toxicity possibly related to the CAR-GPC3 T cells.

Secondary Outcome Measures :
  1. Engraftment: the DNA vector copies per mL blood of CAR-GPC3 T cells [ Time Frame: 2 years ]
    The DNA vector copies per mL blood of CAR-GPC3 T cells on week 4 after the first infusion by Q-PCR. Q-PCR for CAR-GPC3 vector sequences will also be performed after infusion thereafter until any 2 sequential tests are negative documenting loss of CAR-GPC3 T cells within 2 years.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men or women aged 18~70 years old
  2. Subjects are diagnosed as refractory, recurrent ,metastatic, advanced lung squamous cell carcinoma by histological and cytological methods including specific lesion-targeted brush biopsy, lavage and fine needle aspiration;
  3. Have at least one new measurable tumor lesion compared with previous irradiated region
  4. Tumor tissues samples confirmed as GPC3-positive
  5. Expected survival≥12 weeks
  6. ECOG scored as 0-1 or KPS grading > 80
  7. ANC≥1500/nm3
  8. PLT≥100000/mm3
  9. Hb≥9.0g/dL
  10. Serum creatinine≤2.5mg/dL,CCR≥50ml/min (renal malfunction defined as CCR<50ml/min according to Cockroft-Gault formula)
  11. ALT and AST≤2.5ULN; for liver metastasis,ALT and AST ≤5ULN
  12. Serum TBiL≤3.0mg/dL, TBiL≤2.5ULN
  13. PT: INR < 1.7 or extended PT to normal value < 4s
  14. Adequate venous access for apheresis or venous blood collection, and no other contraindication of blood cell separation
  15. Patients with willingness to be in this study and able to provide informed consent
  16. Capable of receiving treatment and follow up, included subjects are required to receive treatment in the enrolled centre
  17. Women of childbearing age are required to take acceptable measures to minimize the possibility of pregnancy during whole session. Women of childbearing age must have negative results of serum or urine tests within 24 hours prior to infusion. Women subjects must not be in lactation;

Exclusion Criteria:

  1. CAR-T positive rate < 10%
  2. pregnant women or women in lactation
  3. active HBV or HCV infection
  4. HIV/AIDS infection
  5. active infection
  6. previously suffered from diseases or concurrent diseases as followed:

    • patients confirmed as severe autoimmune diseases in long-term (over 2 months) need of systemic immune inhibitors (steroid) or as immune-mediated symptomatic diseases including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune vasculitis (for example, Wegener's granulomatosis)
    • subjects with previous diagnosis as motor neurone disease caused by autoimmunity
    • subjects previously suffered from toxic epidermal necrolysis (TEN)
    • subjects with any mental diseases including dementia, mental status change that may impinge the understanding and performance of informed consent and related questionnaire
    • subjects with severe, uncontrollable diseases judged by investigators that may hinder them receiving this treatment
    • subjects with previously active malignant tumors including basal or squamous skin cancer, superficial bladder cancer, and in situ breast carcinoma within 5 years who had been completely cured without the need of follow-up treatment are not excluded.
  7. during ongoing treatment using systemic steroid or steroid inhalants
  8. previous treatment used gene therapy products
  9. previous experience of immunotherapies including CIK, DC, DC-CIK, LAK for the treatment of cancer
  10. allergic to immunotherapies or related drugs
  11. patients in need of treatment for heart disease with ≥2 NYHA or for poor controlled hypertension
  12. subjects with unstable or active peptic ulcer or alimentary tract hemorrhage
  13. subjects with previous organ transplantation or ready for organ transplantation
  14. subjects in need of anticoagulant therapy treatment (warfarin or heparin)
  15. subjects judged by investigators as not appropriate for this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02876978

Layout table for location contacts
Contact: Li Zonghai, MD 86-21-54489926 ext 817
Contact: Ruan Huaying, bachelor 86-21-54489926 ext 806

Layout table for location information
China, Shanghai
Shanghai Chest Hospital,Shanghai Jiaotong University Recruiting
Shanghai, Shanghai, China, 200030
Sponsors and Collaborators
CARsgen Therapeutics Co., Ltd.
Layout table for investigator information
Principal Investigator: Jiang Liyan, MD Shanghai Chest Hospital,Shanghai Jiaotong University
Layout table for additonal information
Responsible Party: CARsgen Therapeutics Co., Ltd. Identifier: NCT02876978    
Other Study ID Numbers: CG1003
First Posted: August 24, 2016    Key Record Dates
Last Update Posted: August 24, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists